Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P11836
UPID:
CD20_HUMAN
Alternative names:
B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1
Alternative UPACC:
P11836; A6NMS4; B4DT24; P08984; Q13963
Background:
B-lymphocyte antigen CD20, also known as Bp35, plays a pivotal role in B-cell development, differentiation, and activation. This membrane protein is crucial for regulating cellular calcium influx, a key process for B-lymphocyte functions.
Therapeutic significance:
CD20's involvement in Immunodeficiency, common variable, 5, highlights its potential as a therapeutic target. By understanding CD20's role, novel strategies for treating antibody deficiencies and recurrent infections could be developed.